Last reviewed · How we verify

DepoCyte — Competitive Intelligence Brief

DepoCyte (DepoCyte) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Liposomal chemotherapy (nucleoside antimetabolite). Area: Oncology.

marketed Liposomal chemotherapy (nucleoside antimetabolite) DNA synthesis (cytarabine acts as a nucleoside analog) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DepoCyte (DepoCyte) — PETHEMA Foundation. DepoCyte is a sustained-release formulation of cytarabine that delivers chemotherapy directly into the cerebrospinal fluid to treat hematologic malignancies affecting the central nervous system.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DepoCyte TARGET DepoCyte PETHEMA Foundation marketed Liposomal chemotherapy (nucleoside antimetabolite) DNA synthesis (cytarabine acts as a nucleoside analog)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Liposomal chemotherapy (nucleoside antimetabolite) class)

  1. PETHEMA Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DepoCyte — Competitive Intelligence Brief. https://druglandscape.com/ci/depocyte. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: